- ALLEN L. SILVEY JR - DO
- PETER J. SACCONE - DO
Our Clinical Research Department is dedicated to improving patient care through innovative research, evidence-based medicine, and collaboration with leading healthcare professionals and organizations. We conduct high-quality clinical trials that help bring new treatments, therapies, and medical advancements to patients safely and effectively.
Our mission is to advance medical knowledge and improve patient outcomes by conducting ethical, patient-centered clinical research in a safe, compassionate, and professional environment.
We are committed to:
Clinical research is the study of health and illness in people. Clinical trials are research studies that are conducted in humans to answer specific questions about new therapies, vaccines, surgical procedures or diagnostic tests. They may also evaluate new ways of using current treatments. The trials are carefully designed, reviewed and completed, and need to be approved before they can start.
Joining a clinical study is a personal decision. People participate in clinical trials for a variety of reasons, including:
Participating in clinical research can help future generations live healthier lives. Major medical breakthroughs would not be possible without the collaboration of clinical trial participants!
We regularly enroll participants in ongoing clinical trials for a variety of medical conditions. To learn more about currently recruiting studies or eligibility, please contact our Clinical Research Department.
Your privacy is important to us. The information you share in this online form for communication purposes will be treated confidentially and will only be used to facilitate the intended conversation, Data may be shared with Third-Parties and those third parties are processing this data in a limited capacity to the extent allowed by contract or legal obligation.
STRIDE-A : Global, multicenter observational study to prospectively describe the real-world effectiveness of depemokimab in patients with asthma with Type-2 inflammation
AIRITY : A hybrid cross-sectional and prospective study to assess patient characteristics, disease control, phenotypes, endotypes, and outcomes in a real-world setting in patients with asthma
EMBARK : A multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study to evaluate the efficacy and safety of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (COPD)
ENDURA-2 : A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type-2 inflammation
REALITI-C : Real-world effectiveness of mepolizumab in treating chronic obstructive pulmonary disease: a multi-country prospective study
BOSTON-II : Diagnostic performance of small RNA blood test in patients undergoing follow-up imaging after positive low dose CT screening for cancer of the lung
REIMAGINE : A prospective, real-world, interventional study to evaluate the effect of mepolizumab on achieving clinical remission in participants with severe asthma
PERFORM : A Phase 4, 52-week (primary analysis at 24-weeks), randomized, stratified, open-label, active-controlled, parallel-group, effectiveness study, comparing FF/UMEC/VI with non-ellipta usual care (ICS/LABA) in adult participants with uncontrolled asthma
SHIELD : Screening for high frequency malignant disease
DELFI-L 101 : DNA Evaluation of fragments for early interception – lung cancer training study
Time and Motion : Time and Motion (T&M) study to quantify time and resources associated with the management and administration of injectable biologics to treat patients with Severe Asthma (SA) and/or Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)